✦ LIBER ✦

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

✍ Scribed by Asahina, H; Yamazaki, K; Kinoshita, I; Sukoh, N; Harada, M; Yokouchi, H; Ishida, T; Ogura, S; Kojima, T; Okamoto, Y; Fujita, Y; Dosaka–akita, H; Isobe, H; Nishimura, M

Book ID: 120663843
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 139 KB
Volume: 95
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6603393

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib as first-line treatment for pa

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Prospective phase II study of gefitinib

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

✍ Sugio, Kenji; Uramoto, Hidetaka; Onitsuka, Takamitsu; Mizukami, Makiko; Ichiki, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Prospective Phase II Study of Gefitinib

Prospective Phase II Study of Gefitinib for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

✍ Inoue, A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 262 KB

9123 POSTER Final Results of a Phase II

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

✍ Asami, K.; Koizumi, T.; Hirai, K.; Ameshima, S.; Tsukadaira, A.; Morozumi, N.; M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

OP3 Cost-effectiveness of epidermal grow

OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer

✍ G. de Lima Lopes; J. Segel; D. Tan; Y. Do; T. Mok; E. Finkelstein 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB

A phase II trial of gefitinib as mainten

A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China

✍ Lu Yang; Zhi-jie Wang; Tong-tong An; Hua Bai; Jun Zhao; Jian-chun Duan; Ping-pin 📂 Article 📅 2010 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 283 KB